IP Library Granted Patent US 10,279,025
Granted Patent B2
US 10,279,025 · App. 15/623,478 · Granted May 7, 2019

LPS vaccine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,279,025
App. No.
15/623,478
Granted
May 7, 2019
Kind
B2
Abstract

A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

Claims (12)

1. A composition comprising lipopolysaccharide from Salmonella,

wherein the Salmonella is one or more Salmonella groups selected from the group consisting of O4, O7 and O9, and

wherein the composition comprises at least one purified lipopolysaccharide O-antigen from Salmonella Enteritidis, Salmonella Typhimurium , and Salmonella Infantis , provided that said O-antigen is not comprised in a whole cell.

2. The composition of claim 1 , further comprising at least one of an antigen from Newcastle disease virus, an antigen from avian infectious bronchitis virus, an antigen from Mycoplasma gallisepticum , an antigen from Egg drop syndrome virus, or an antigen from Haemophilus paragallinarum.

3. The composition of claim 1 , comprising the O-antigen in an amount of at least 5,400 EU/ml.

4. The composition of claim 1 , comprising the O-antigen in an amount of at least 54,000 EU/ml.

5. The composition of claim 1 , comprising two of the purified lipopolysaccharide O-antigens.

6. The composition of claim 1 , comprising three of the purified lipopolysaccharide O-antigens.

7. The composition of claim 1 , further comprising an adjuvant.

8. The composition of claim 1 , wherein the O-antigen is not bound to a carrier protein.

9. The composition of claim 1 , wherein the O-antigen is bound to a carrier protein.

10. The composition of claim 9 , wherein the carrier protein is selected from the group consisting of diphtheria toxoid (DT), tetanus toxoid (TT), cholera toxin (CT) and CRM197.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2022
From: KM BIOLOGICS CO., LTD.
To: MEIJI ANIMAL HEALTH CO., LTD.
Reel/Frame 060927/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →